adamantane has been researched along with MS (Multiple Sclerosis) in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Grieb, P; Rejdak, K | 1 |
| Chen, JZ; Duan, YH; Gunosewoyo, H; Ji, YY; Li, J; Shi, Y; Tang, J; Wang, ZL; Wu, YR; Xie, X; Xie, XY; Yang, F; Yu, LF | 1 |
| Annunziata, P; Cioni, C; Corelli, F; Mugnaini, C | 1 |
3 other study(ies) available for adamantane and MS (Multiple Sclerosis)
| Article | Year |
|---|---|
Adamantanes might be protective from COVID-19 in patients with neurological diseases: multiple sclerosis, parkinsonism and cognitive impairment.
Topics: Adamantane; Adult; Aged; Aged, 80 and over; Amantadine; Asymptomatic Infections; Betacoronavirus; Cognitive Dysfunction; Coronavirus Infections; COVID-19; Dopamine Agents; Female; Humans; Male; Memantine; Middle Aged; Multiple Sclerosis; Pandemics; Parkinson Disease; Pneumonia, Viral; Protective Factors; SARS-CoV-2; Severity of Illness Index | 2020 |
Amidoalkylindoles as Potent and Selective Cannabinoid Type 2 Receptor Agonists with in Vivo Efficacy in a Mouse Model of Multiple Sclerosis.
Topics: Adamantane; Animals; Cannabinoid Receptor Agonists; Cannabinoid Receptor Antagonists; CHO Cells; Cricetulus; Female; Indoles; Ligands; Mice, Inbred C57BL; Molecular Docking Simulation; Multiple Sclerosis; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Structure-Activity Relationship | 2017 |
Potent immunomodulatory activity of a highly selective cannabinoid CB2 agonist on immune cells from healthy subjects and patients with multiple sclerosis.
Topics: Adamantane; Adult; Cannabinoid Receptor Agonists; Cells, Cultured; Cytokines; Female; Humans; Immunologic Factors; Leukocytes, Mononuclear; Male; Multiple Sclerosis; Quinolones; Receptor, Cannabinoid, CB2; T-Lymphocytes | 2017 |